Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations

Trial Profile

Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Ivacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.
    • 07 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top